#United States #Atlanta #Drug Development #Radyus Research #Eurofins CDMO

Radyus Research and Eurofins CDMO Alphora Forge Strategic Alliance

In a groundbreaking announcement on May 28, 2025, Radyus Research, a prominent U.S.-based drug development organization, embarked on a strategic partnership with Eurofins CDMO Alphora, a leading Canadian contract development and manufacturing organization. This collaboration is set to transform the landscape of early-stage drug development for biotech companies across the globe.

A New Era in Drug Development

The partnership is premised on a mutual commitment to excellence in research and development (R&D) operations through sustained client relationships. By marrying their respective capabilities in preclinical development and clinical proof-of-concept stages, Radyus and Alphora intend to cultivate a combined service portfolio that addresses inefficiencies within the drug development process, reduces unnecessary transitions, and enhances the probability of success for drug programs.

Radyus Research brings a wealth of expertise in various core areas including drug development strategies, efficacy and safety testing on animals, regulatory planning, clinical trial operations, and overall program management. On the manufacturing side, Eurofins CDMO Alphora is recognized for its robust capabilities in process development and Good Manufacturing Practice (GMP) manufacturing of small molecule active pharmaceutical ingredients (APIs), biologics, and drug products.

Insights from Leadership

"We are thrilled to initiate this partnership and add significant value for our clients," expressed Marta New, CEO of Radyus Research. "This collaboration embodies our shared belief that long-term partnerships rather than transactional relationships are essential for efficient drug development. Together, we are assembling a world-class, globally synchronized team dedicated to delivering outstanding results."

Echoing this sentiment, Eurofins CDMO Alphora underscored the advantages this alliance brings. "This collaboration enhances our capacity to deliver unified strategies combined with excellence throughout the development continuum," the company stated. They noted the importance of building a model founded on trust, reflective of the modern, collaborative framework of the biopharmaceutical industry.

Towards a Unified Approach

Together, Radyus Research and Eurofins CDMO Alphora aim to pioneer a new standard in early-stage drug development through their integrated services. Their focus on long-term client success will not only benefit their partnerships but also enhance the overall landscape of biotech innovation.

About Radyus Research

Radyus Research specializes in integrated drug development services. Their expertise covers preclinical and early clinical program strategies, regulatory submissions, and driving multidisciplinary program management. With a milestone-oriented methodology, Radyus supports biotech organizations from the optimization of leads through the validation stages of novel therapeutics and vaccines.

About Eurofins CDMO Alphora

Eurofins CDMO Alphora is known for providing comprehensive solutions in process development and GMP manufacturing services for small molecule APIs, drug products, and biologics. Their support extends from the nascent stages of development all the way to commercialization, backed by the extensive scientific knowledge and geographical footprint of the global Eurofins network. This network grants clients access to advanced analytical services, toxicology, bioanalysis, clinical logistics, and research into biomarkers.

Conclusion

The collaboration between Radyus Research and Eurofins CDMO Alphora marks a significant development for the pharmaceutical sector. By streamlining operations and fostering cooperative engagement, they are poised to make a remarkable impact on the efficiency and success rates of drug development for biotech companies around the world.